Maryland Passes Veterinary Cannabis Bill, Protecting Vets Who Discuss CBD With Pet Owners

Maryland’s House of Delegates unanimously passed a bill that protects veterinarians from licensing board discipline when they discuss cannabis-based treatment options with pet owners. The speech-and-professional-judgment protection statute takes effect October 1, 2026, making Maryland one of the first states to formally remove the chilling effect that has kept many vets silent on the topic.

What the Bill Does

The legislation draws a clear line: veterinarians can discuss cannabis products, including CBD, with animal owners without risking their professional license. Before this bill, Maryland vets operated in a gray zone. State licensing boards had the authority to investigate and potentially discipline any veterinarian who recommended or even discussed cannabis-derived products in a clinical setting.

That ambiguity forced many vets into uncomfortable positions. Some refused to answer questions about CBD entirely. Others gave vague, noncommittal responses that left pet owners to navigate the market on their own. The new law does not require veterinarians to recommend cannabis products. It simply guarantees that those who choose to discuss them will not face professional consequences for doing so.

“Pet owners have been asking about CBD for years. We had the research in front of us but couldn’t say a word without worrying about our license. This bill fixes that.”

The unanimous vote signals broad bipartisan support. No delegate voted against the measure, and the bill moved through committee with minimal opposition.

Why Veterinarians Stayed Silent

The problem was never a lack of interest. Surveys from the American Veterinary Medical Association show that more than 60 percent of pet owners have asked their vet about CBD at least once. Most received little useful guidance.

Veterinarians are bound by state licensing boards that set standards of practice. In states without explicit protections, discussing an unregulated product can be framed as unprofessional conduct. The risk was career-ending discipline over a conversation.

This created a knowledge gap. Pet owners turned to internet forums, social media, and retail staff for dosing and product guidance instead of trained medical professionals. The Maryland bill aims to close that gap by putting veterinary judgment back at the center of the decision.

For pet owners exploring CBD options, CBDPet.com offers research-backed guidance on products formulated specifically for animals.

The Research Driving the Conversation

A growing body of veterinary CBD research has made the old silence harder to justify. A landmark study published in late 2025 tracked 47,000 dogs and documented measurable behavior shifts associated with CBD supplementation. The scale of that study gave it weight that smaller trials could not match.

Ongoing research is examining CBD’s effects in several areas of veterinary medicine:

• Osteoarthritis in dogs: Multiple clinical trials are evaluating whether CBD reduces joint pain and improves mobility in aging dogs. Early results have shown enough promise to justify larger, placebo-controlled studies.
• Seizure management: Canine epilepsy studies are testing CBD as an adjunct to conventional anticonvulsant medications. Researchers are tracking seizure frequency, severity, and quality-of-life markers.
• Feline dermatological conditions: Newer studies are looking at CBD’s effects on skin inflammation and allergic responses in cats, an area with very limited prior research.

None of these studies have produced FDA-approved veterinary treatments. But the data is accumulating fast enough that veterinarians want to be part of the conversation. Maryland’s bill lets them participate without professional risk.

Understanding third-party lab testing and product quality standards remains important for pet owners evaluating CBD products for their animals.

A $600 Million Market With Limited Professional Guidance

The pet CBD market is valued at roughly $600 million in 2026. That number has grown steadily even without veterinary endorsement. Pet owners are buying CBD oils, treats, topicals, and chews from online retailers, pet stores, and dispensaries.

The disconnect between market size and professional involvement has been a persistent problem. Without veterinary input, pet owners have no reliable way to evaluate dosing, drug interactions, or product quality. They rely on brand marketing and user reviews instead of clinical advice.

Maryland’s bill does not regulate pet CBD products themselves. It does not set dosing standards or require veterinary prescriptions. What it does is remove the barrier that kept the most qualified professionals out of the conversation. That alone could reshape how pet owners approach CBD for their animals.

Other states are watching. California passed a similar protection for veterinarians in 2022, and Nevada followed in 2023. Maryland’s unanimous vote adds momentum to a trend that appears likely to spread further. Advocates in at least five additional states have introduced comparable legislation in 2026.

What This Means for Pet Owners

Starting October 1, Maryland pet owners can expect more direct answers from their veterinarians. That does not mean every vet will recommend CBD. Some will remain skeptical, and that skepticism is valid given the current state of the evidence. But the legal barrier to honest conversation will be gone.

Pet owners should still do their homework. Not all CBD products are created equal, and the pet CBD market has the same quality-control challenges as the human market. Look for products with verified lab results and transparent ingredient lists. Ask your vet about potential interactions with existing medications. Start with conservative doses and monitor your pet’s response.

The bill also matters for veterinary education. With the legal risk removed, veterinary schools and continuing education programs in Maryland can incorporate cannabis science into their curricula without liability concerns. That pipeline of knowledge will take time to develop, but the legal foundation is now in place.

Maryland’s unanimous vote sends a clear signal: the state wants its veterinarians to be able to practice with full professional judgment on this topic. Whether the rest of the country follows will depend on how smoothly implementation goes after October 1.

These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.